Case Studies

A life science venture capital fund was contemplating investing in advanced plasma product opportunities being developed by a biopharmaceutical company. Alacrita was commissioned to provide a reality...

10111A world-leading manufacturer of wound care products was assessing opportunities in advanced wound care, and has mapped regulatory pathways that pertained to various classes of product. Having...

Drawing on expertise from its regulatory, gene therapy and manufacturing consultants, Alacrita conducted feasibility study and formulated a business case for a new GMP facility for production of...

Oncology company with a preclinical project seeking finance and potential acquisition For a virtual life science company, Alacrita helped establish a valuation trajectory for one of their products,...

Challenge: Anti-nerve growth factor inhibitors are a new class of powerful analgesics in clinical development. They were put on clinical development hold by the FDA in 2012 due to joint-related...

Alacrita's consulting team supports a number of pharmaceutical & biotech companies with medical and clinical strategy. We have particular depth in oncology, but also have expertise in infectious...

On behalf of a private equity (PE) investor, an Alacrita partner was retained as an observer on the board of a regenerative medicine/advanced wound healing company where he contributed to BoD...

Asset scouting for a well-capitalized Swiss pharma company Alacrita been engaged by a well-capitalized Swiss pharma company to scout and identify early stage in-licensing opportunities from the New...

Challenge: The technology transfer function of a leading cancer research institute needed a development plan for a promising small molecule lead series against a novel anti-invasion/anti-metastasis...

Challenge: An emerging specialty pharma company facing an urgent partnering transaction deadline needed to assess the likely reimbursement and pricing of a new therapy in a crowded haematology...

Medical device 510(k) submission strategy Alacrita’s client had successfully CE marked a novel lung function device, and the next step in the commercial strategy was to obtain 510(k) clearance to...

A venture-backed biotech company, developing a clinical stage asset for the treatment of early stage cancer, was populating a dataroom and preparing for negotiations with a major pharmaceutical...